OVID - NASDAQ

Ovid Therapeutics Inc.

OVID·NASDAQ

$2.46

+2.6%

HealthcareBiotechnology

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$324.70M

EPS-0.2400

P/E Ratio-10.26

Earnings Date08/12/2026

150.93M

Assets

64%

3Y-3.0%

5Y+99.0%

10Y+185.0%

20.27M

Total Liabilities

-15%

3Y-12.0%

5Y-37.0%

10Y+443.0%

130.66M

Total Equity

92%

3Y-1.0%

5Y+199.0%

10Y+165.0%

Ovid Therapeutics Inc. Funding & Solvency Profile

OVID · NASDAQ

Current Assets

Cash & Cash Equivalents13.15M

Net Receivables0.00

Inventory0.00

Other Current Assets20.81M

Total Current Assets90 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments64.70M

Other Non-Current Assets-4.22M

Total Non-Current Assets60 M

Total Assets

150.93M

Financial Health Analysis

Current Ratio

10.91x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.16x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

82 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

60% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Ovid Therapeutics Inc. Balance Sheet

OVID • NASDAQ

Ovid Therapeutics Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	13.2M	26.3M	27M	44.9M	187.8M	72M	41.9M	36.5M	87.1M	51.9M	69.9M	4.8M
Short-Term Investments	56.5M	26.8M	78.8M	84.1M	0.0	0.0	34.8M	5M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	69.6M	53.1M	105.8M	129M	187.8M	72M	76.7M	41.5M	87.1M	51.9M	69.9M	4.8M
Net Receivables	0.0	0.0	0.0	0.0	0.0	141.8K	1.1M	0.0	0.0	7.4K	58.6K	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	141.8K	1.1M	0.0	0.0	7.4K	58.6K	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	242.7K	0.0	0.0
Prepaids	0.0	2.9M	3.8M	2.4M	0.0	2.7M	1.9M	2.2M	1.5M	221.5K	280.3K	769.0
Other Current Assets	20.8M	0.0	1K	1.0	2.7M	0.0	0.0	600.1K	0.0	242.7K	0.0	0.0
Total Current Assets	90.4M	55.9M	109.6M	131.4M	190.5M	74.8M	79.8M	44.3M	88.6M	52.4M	70.3M	4.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	13.2M	14.7M	16.1M	242.8K	135.6K	68.4K	69.9K	51.8K	43.6K	29.5K	1.3K
Goodwill	0.0	0.0	0.0	0.0	0.0	100.0	-247.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	92K	200K	222.1K	164K	318.9K	467.2K	391.9K	124.2K	110.1K	18.9K	2.5K
Goodwill & Intangible Assets	0.0	92K	200K	222.1K	164K	319K	467K	391.9K	124.2K	110.1K	18.9K	2.5K
Long-Term Investments	64.7M	21M	17.6M	5.6M	3.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	-4.2M	1.9M	1.9M	2M	96.1K	627.8K	495.2K	2.9M	693.6K	463K	44.9K	6.5K
Total Non-Current Assets	60.5M	36.2M	34.4M	23.9M	4.1M	1.1M	1M	3.4M	869.6K	616.7K	93.3K	10.4K
Other Assets	0.0	0.0	0.0	0.0	0.0	-100.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	150.9M	92.2M	144M	155.3M	194.5M	75.9M	80.8M	47.6M	89.5M	53M	70.4M	4.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2M	3.2M	3.7M	2M	7.1M	7.8M	3.3M	3.8M	2M	857.2K	671.6K	79.1K
Accounts Payable	2M	3.2M	3.7M	2M	7.1M	5.4M	3.3M	3.8M	2M	857.2K	670.5K	79.1K
Other Payables	0.0	0.0	0.0	0.0	0.0	2.4M	0.0	0.0	0.0	0.0	1K	0.0
Accrued Expenses	4.9M	6M	6.5M	4.5M	3.8M	3.8M	2.7M	2.8M	1.9M	2.9M	1.6M	40.8K
Capital Lease Obligations (Current)	1.4M	1.3M	1.2M	533.9K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	2.2M	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	0.0	1K	0.0	0.0	3.9M	8.2M	4.5M	2.3M	2.1M	0.0	-1K	0.0
Total Current Liabilities	8.3M	10.5M	11.5M	7M	14.8M	22.1M	10.5M	8.8M	6M	3.7M	2.3M	120K
NON-CURRENT LIABILITIES
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	10.2M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	30M	1.0	0.0	61.2K	286.6K	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	12M	13.4M	44.8M	16M	0.0	10.2M	286.6K	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	13.4M	14.8M	16M	16.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	20.3M	23.9M	56.2M	23M	14.8M	32.3M	10.8M	8.8M	6M	3.7M	2.3M	120K
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	1.0	1.0	3.0	8.0	0.0	0.0	8K	8K	5.1K
Common Stock	130K	71K	71K	70.5K	70.4K	65.7K	54.7K	24.7K	24.6K	19.6K	9.8K	20K
Additional Paid-In Capital	452.4M	372.5M	365.6M	357.8M	351M	337.8M	283.1M	191.5M	184.1M	85.2M	81.5M	5M
Retained Earnings	-321.7M	-304.3M	-277.9M	-225.5M	-171.4M	-294.2M	-213.2M	-152.7M	-100.7M	-61.8M	-13.5M	-335.2K
Accumulated Other Comprehensive Income/Loss	-202K	-35K	0.0	-42.2K	0.0	0.0	2.5K	-1.8K	-50.9K	-20.2K	-3.9K	0.0
Total Stockholders' Equity	130.7M	68.2M	87.8M	132.3M	179.7M	43.6M	70M	38.8M	83.4M	49.3M	68.1M	4.7M
Total Equity	130.7M	68.2M	87.8M	132.3M	179.7M	43.6M	70M	38.8M	83.4M	49.3M	68.1M	4.7M
SUMMARY
Total Liabilities & Equity	150.9M	92.2M	144M	155.3M	194.5M	75.9M	80.8M	47.6M	89.5M	53M	70.4M	4.9M
Total Investments	121.2M	47.7M	96.4M	89.8M	3.6M	0.0	34.8M	5M	0.0	0.0	0.0	0.0
Total Debt	13.4M	14.8M	16M	16.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	266K	-11.5M	-11M	-28.3M	-187.8M	-72M	-41.9M	-36.5M	-87.1M	-51.9M	-69.9M	-4.8M
Shares Outstanding	71,109,514	71,109,514	71,109,514	71,109,514	71,109,514	71,109,514	71,109,514	71,109,514	71,109,514	71,109,514	71,109,514	71,109,514

SEC Filings

OVID - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	May 29, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 27, 2026	December 31, 2025	2025	View Filing
S-3 S-3 N/A	April 21, 2026	April 21, 2026		View Filing
8-K 8-K 2026 N/A	April 20, 2026	April 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 18, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 18, 2026	March 17, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 18, 2025	2025	View Filing
S-3 S-3 N/A	December 15, 2025	December 15, 2025		View Filing

Showing 1 to 10 of 195 filings

Related Guides

Blog Categories

Continue your OVID research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.